A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Bupropion

Trial Profile

A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Bupropion

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Amenamevir (Primary) ; Bupropion
  • Indications Herpes simplex virus infections; Herpes zoster
  • Focus Pharmacokinetics
  • Sponsors Maruho
  • Most Recent Events

    • 17 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 07 Jun 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top